BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 31, 2025
Home » Authors » Amanda Pedersen

Articles by Amanda Pedersen

Engaged Under Pressure: Heartware nixes Valtech deal citing 'different set of circumstances'

Jan. 29, 2016
By Amanda Pedersen
Just three weeks after vehemently defending its proposed acquisition of Valtech Cardio Ltd. (Yehuda, Israel), Heartware International Inc. (Framingham, Mass.) nixed the stock-based deal, which was valued at $929 million and announced in September.
Read More

M&A Talk Piques Interest: J&J gets off the deal sidelines and goes on the prowl for good 2016 buys

Jan. 28, 2016
By Amanda Pedersen
With nearly $20 billion of net cash, the industry can expect to see "disciplined and decisive actions" from Johnson & Johnson (J&J; New Brunswick, N.J.) regarding mergers and acquisitions this year, CEO Alex Gorsky said during the company's fourth-quarter earnings call.
Read More

MDD's Cardiology Extra

Jan. 26, 2016
By Amanda Pedersen

Useful for patients and for clinical trials: Adherium wants to make inhalers smarter for the user

Jan. 25, 2016
By Amanda Pedersen
Inhalers are getting smarter with the help of digital health technology from Adherium Group (Auckland, New Zealand). CEO Garth Southerland, who has had severe asthma his entire life, founded the company in 2001.
Read More

Exosome launchesRNA-based lung cancer test

Jan. 22, 2016
By Amanda Pedersen

Substantial Reduction in IOP with stent: Glaukos Istent shows long-term promise for glaucoma, stock up

Jan. 21, 2016
By Amanda Pedersen
While stocks fell deep into the red across the board Wednesday, Glaukos Corp.'s (Laguana Hills, Calif.) share price (NYSE; GKOS) moved into the g reen by just a pinch after the company reported positive long-term data from an international study of its micro-bypass stent for glaucoma.
Read More

J.P. Morgan HealthCare Conference 2016: Surgeons about to get new surgical robot alternatives to daVinci system

Jan. 19, 2016
By Amanda Pedersen
SAN FRANCISCO — Surgeons have only had one robot to play with in the general surgery space since Intutive Surgical Inc. (Sunnyvale, Calif.) introduced the da Vinci system in 1999, but that's about to change as Transenterix Inc. (Morrisville, N.C.) prepares to launch its recently-acquired Alf-x robotic system in Europe and its Surgibot system in the U.S.
Read More

J.P. Morgan HealthCare Conference 2016: Endologix touts merger benefits: tech, growth, profit

Jan. 15, 2016
By Amanda Pedersen

Significant drop in M&As in fourth quarter

Jan. 14, 2016
By Amanda Pedersen

J.P. Morgan Healthcare Conference 2016: Medtronic to return $5 billion of freed cash to shareholders

Jan. 13, 2016
By Amanda Pedersen
SAN FRANCISCO — As Medtronic plc (Dublin) approaches the anniversary of its blockbuster Covidien deal, which closed a year ago this month, the company is making strides to prove the $42.9 billion acquisition is paying off.
Read More
Previous 1 2 … 15 16 17 18 19 20 21 22 23 … 222 223 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 31, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 30, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing